Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Download Data

Freeline Therapeutics Holdings Plc Debt to Tangible Net Worth Ratio for the quarter ending September 30, 2023

Freeline Therapeutics Holdings Plc Debt to Tangible Net Worth Ratio is NA for the quarter ending September 30, 2023. The debt to tangible net worth ratio measures the level of debt relative to a company's tangible net worth. It is calculated by dividing total debt by the difference between shareholders' equity and intangible assets (such as goodwill). This ratio provides insights into the company's financial leverage, excluding intangible assets. A higher ratio suggests a higher level of debt burden in relation to tangible net worth.
NASDAQ: FRLN

Freeline Therapeutics Holdings Plc

CEO Mr. Michael J. Parini J.D.
IPO Date Aug. 7, 2020
Location United Kingdom
Headquarters Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Employees 152
Sector Healthcare
Industry Biotechnology
Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Similar companies

AVRO

AVROBIO Inc

NA

NA

IMMX

Immix Biopharma Inc

NA

NA

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email